Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia

This study aims to learn about the safety, tolerability, and different dose levels' safety profiles of Venetoclax and Bomedemstat (VenBom) combination therapy in participants with relapsed or refractory acute myeloid leukemia.

Trial Details

NCT ID
NCT05597306
Phase
PHASE1
Sponsor
Terrence J Bradley, MD
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Bomedemstat
  • Venetoclax
Locations (sample)
  • Miami, Florida, United States|25.77427,-80.19366

Key Eligibility Criteria

  • A. Confirmed diagnosis of one of the following:
  • 1\. Relapsed/refractory Acute Myeloid Leukemia (AML) following failure of at least one standard, front-line therapy. Patients must have an AML diag…
  • B. Adult male or female patients 18 years of age or older.
  • C. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2 (Appendix A: Performance Status Scales).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →